arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Xilio Therapeutics, Inc.

XLO

$9.16 ▼ -0.01 (-0.05%) at close

7 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Xilio Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $76.6M

Dividend Yield —

Revenue Growth 589.9%

Op. Margin -95.9%

ROIC -119.0% ↗

FCF / Share $-0.66 ↗

Trailing P/E —

Price / Book 1.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$43.77M

↑ +589.9% —

Net Income Profit after all expenses

$-35.04M

↑ +39.8% —

FCF / Share Free cash flow per share

$-0.66

↑ +86.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	589.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+7274%)	—	—	—	—	—	—
EPS Growth YoY (%)	72.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-448.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	13.7% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	76.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	87.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	39.8% Excellent ↑ Excellent Improving Year-over-year change in net income	23.8% Good ↑ Good Improving Year-over-year change in net income	13.4% Fair ↑ Fair Improving Year-over-year change in net income	-16.4% Weak Weak Year-over-year change in net income	-37.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	86.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-91.7% Weak ↓ Weak Declining Year-over-year change in free cash flow	11.3% Fair ↓ Fair Declining Year-over-year change in free cash flow	80.6% Excellent Excellent Year-over-year change in free cash flow	80.0% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	-95.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-739%)	—	—	—	—	—	—
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
Profit Margin (%) (%)	-80.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-767%)	—	—	—	—	—	—
FCF Margin (%) (%)	-12.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-290.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—
FCF / Net Income (x)	0.16x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.32x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.08x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-119.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-344.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-169.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-66.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-32.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	51.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-27.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-85.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-129.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-64.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-34.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-150.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-99.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-762%)	—	-207.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1483%)	-83.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-657%)	-40.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-373%)	66.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+342%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	-977.13x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-138.10x Weak → Weak Stable Operating income divided by interest expense Optimal: > 5x	-160.63x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-152.53x Weak Weak Operating income divided by interest expense Optimal: > 5x	-101.80x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-137.53M	$-55.29M	$-44.70M	$-120.39M	$-198.05M	$-19.24M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$5.24	$1.66	—	—	—	—	—
Basic EPS, GAAP (USD)	$-4.19	$-15.24	$-2.78	$-3.22	$-13.52	$-105.42	—
Free Cash Flow per Share (USD)	$-0.66	$-4.82	$-2.51	$-2.83	$-14.60	$-73.08	—
Book Value per Share (USD)	$7.79	$5.38	$1.33	$3.85	$6.78	$-120.72	—
Tangible Book Value per Share (USD)	$7.79	$5.38	$1.33	$3.85	$6.78	$-120.72	—
Basic Weighted Avg Shares (shares)	8.36M	3.82M	27.50M	27.39M	5.61M	523,786	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$88.75M	$32.97M	$32.17M	$103.38M	$189.74M	$-1.56M	—
Total Equity (USD)	$35.27M	$17.60M	$36.83M	$105.65M	$185.43M	$-83.29M	$-29.52M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$43.77M	$6.34M	—	—	—	—	—
Depreciation Expense (USD)	$1.54M	$1.64M	$1.90M	$1.85M	$1.50M	$1.06M	—
Net Income, GAAP (USD)	$-35.04M	$-58.24M	$-76.40M	$-88.22M	$-75.80M	$-55.22M	—
Operating Cash Flow (USD)	$-4.99M	$-18.38M	$-68.62M	$-75.72M	$-80.75M	$-36.09M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Xilio Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare XLO with peers